Laurus Labs forms JV company
KRKA holds 51% and Laurus Labs holds 49% shareholding
KRKA holds 51% and Laurus Labs holds 49% shareholding
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Subscribe To Our Newsletter & Stay Updated